Creatd Exits Flyte Stake in $12M Deal with Catheter Precision
Event summary
- Creatd sold its remaining 80% stake in Fly Flyte to Catheter Precision for $6M cash and $6M convertible preferred stock
- Transaction completed on March 10, 2026, strengthening Creatd's balance sheet
- Deal follows a one-year turnaround strategy for Flyte focused on operational optimization
- Creatd retains minority interest in Catheter Precision as part of its investment portfolio
- Proceeds will support Creatd's national exchange listing strategy
The big picture
This transaction aligns with Creatd's strategy of developing businesses for public market readiness while maintaining minority stakes. The deal highlights the company's focus on balance sheet value creation through acquisitions and incubations, particularly in underserved middle-market segments. The $12M exit demonstrates Creatd's ability to monetize turnaround investments while positioning itself as a significant shareholder in NYSE-listed entities.
What we're watching
- Portfolio Strategy
- How Creatd will deploy proceeds to support its national exchange listing without traditional financing structures.
- Investment Returns
- Whether the convertible preferred stock in Catheter Precision will appreciate as part of Creatd's growing investment portfolio.
- Operational Focus
- The pace at which Creatd can institutionalize its turnaround model across additional small-cap and micro-cap companies.
Related topics